Cited by 108Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNeurological Disease Mechanisms and Treatments

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

The prevalence, correlation, and co-occurrence of neuropathology in old age: harmonisation of 12 measures across six community-based autopsy studies of dementia

Open access

Abstract

BACKGROUND: Population-based autopsy studies provide valuable insights into the causes of dementia but are limited by sample size and restriction to specific populations. Harmonisation across studies increases statistical power and allows meaningful comparisons between studies. We aimed to harmonise neuropathology measures across studies and assess the prevalence, correlation, and co-occurrence of neuropathologies in the ageing population. METHODS: We combined data from six community-based autopsy cohorts in the US and the UK in a coordinated cross-sectional analysis. Among all decedents aged 80 years or older, we assessed 12 neuropathologies known to be associated with dementia: arteriolosclerosis, atherosclerosis, macroinfarcts, microinfarcts, lacunes, cerebral amyloid angiopathy, Braak neurofibrillary tangle stage, Consortium to Establish a Registry for Alzheimer's disease (CERAD) diffuse plaque score, CERAD neuritic plaque score, hippocampal sclerosis, limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC), and Lewy body pathology. We divided measures into three groups describing level of confidence (low, moderate, and high) in harmonisation. We described the prevalence, correlations, and co-occurrence of neuropathologies. FINDINGS: The cohorts included 4354 decedents aged 80 years or older with autopsy data. All cohorts included more women than men, with the exception of one study that only included men, and all cohorts included decedents at older ages (range of mean age at death across cohorts 88·0-91·6 years). Measures of Alzheimer's disease neuropathological change, Braak stage and CERAD scores, were in the high confidence category, whereas measures of vascular neuropathologies were in the low (arterioloscerosis, atherosclerosis, cerebral amyloid angiopathy, and lacunes) or moderate (macroinfarcts and microinfarcts) categories. Neuropathology prevalence and co-occurrence was high (2443 [91%] of 2695 participants had more than one of six key neuropathologies and 1106 [41%] of 2695 had three or more). Co-occurrence was strongly but not deterministically associated with dementia status. Vascular and Alzheimer's disease features clustered separately in correlation analyses, and LATE-NC had moderate associations with Alzheimer's disease measures (eg, Braak stage ρ=0·31 [95% CI 0·20-0·42]). INTERPRETATION: Higher variability and more inconsistency in the measurement of vascular neuropathologies compared with the measurement of Alzheimer's disease neuropathological change suggests the development of new frameworks for the measurement of vascular neuropathologies might be helpful. Results highlight the complexity and multi-morbidity of the brain pathologies that underlie dementia in older adults and suggest that prevention efforts and treatments should be multifaceted. FUNDING: Gates Ventures.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2666-7568(23)00019-3

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Crude prevalence and distributions of the 12 included neuropathologies across cohorts (ACT, CC75C, CFAS FHS, HAAS, and ROSMAP) by age group Cohorts were excluded from comparisons when they did not have data on a specific neuropathology. Neuropathologies are grouped into three groups (low, moderate, and high confidence) illustrating the confidence in harmonisation across cohorts based on an assessment of ascertainment methods and comparisons of crude prevalence. Arteriolosclerosis in CC75C is a binary measure and therefore the two categories correspond to absent and present. ACT=Adult Changes in Thought. CC75C=Cambridge City over-75s Cohort Study. CERAD=Consortium to Establish a Registry for Alzheimer's disease. CFAS=Cognitive Function and Ageing Studies. FHS=Framingham Heart Study. HAAS=Honolulu-Asia Aging Study. LATE-NC=limbic-predominant age-related TDP-43 encephalopathy neuropathologic change. ROSMAP=Religious Orders Study and Memory and Aging Project.
Figure 1 Crude prevalence and distributions of the 12 included neuropathologies across cohorts (ACT, CC75C, CFAS FHS, HAAS, and ROSMAP) by age group Cohorts were excluded from comparisons when they did not have data on a specific neuropathology. Neuropathologies are grouped into three groups (low, moderate, and high confidence) illustrating the confidence in harmonisation across cohorts based on an assessment of ascertainment methods and comparisons of crude prevalence. Arteriolosclerosis in CC75C is a binary measure and therefore the two categories correspond to absent and present. ACT=Adult Changes in Thought. CC75C=Cambridge City over-75s Cohort Study. CERAD=Consortium to Establish a Registry for Alzheimer's disease. CFAS=Cognitive Function and Ageing Studies. FHS=Framingham Heart Study. HAAS=Honolulu-Asia Aging Study. LATE-NC=limbic-predominant age-related TDP-43 encephalopathy neuropathologic change. ROSMAP=Religious Orders Study and Memory and Aging Project.CC BY · PubMed Central
Figure 2 Correlation matrix describing inter-variability of neuropathological measures, summarised across cohorts (ACT, CC75C, CFAS FHS, HAAS, and ROSMAP) Correlations were first assessed within each cohort individually, and then pooled together using random-effects meta-analysis. Each cohort contributed to a given correlation when the pair of variables of interest in each correlation existed within a given dataset and were not perfectly collinear (no zero contingency cells). Numbers are shown when the correlation is statistically significant at the level of α=0·05. ACT=Adult Changes in Thought. CC75C=Cambridge City over-75s Cohort Study. CERAD=Consortium to Establish a Registry for Alzheimer's disease. CFAS=Cognitive Function and Ageing Studies. FHS=Framingham Heart Study. HAAS=Honolulu-Asia Aging Study. LATE-NC=limbic-predominant age-related TDP-43 encephalopathy neuropathologic change. ROSMAP=Religious Orders Study and Memory and Aging Project.
Figure 2 Correlation matrix describing inter-variability of neuropathological measures, summarised across cohorts (ACT, CC75C, CFAS FHS, HAAS, and ROSMAP) Correlations were first assessed within each cohort individually, and then pooled together using random-effects meta-analysis. Each cohort contributed to a given correlation when the pair of variables of interest in each correlation existed within a given dataset and were not perfectly collinear (no zero contingency cells). Numbers are shown when the correlation is statistically significant at the level of α=0·05. ACT=Adult Changes in Thought. CC75C=Cambridge City over-75s Cohort Study. CERAD=Consortium to Establish a Registry for Alzheimer's disease. CFAS=Cognitive Function and Ageing Studies. FHS=Framingham Heart Study. HAAS=Honolulu-Asia Aging Study. LATE-NC=limbic-predominant age-related TDP-43 encephalopathy neuropathologic change. ROSMAP=Religious Orders Study and Memory and Aging Project.CC BY · PubMed Central
Figure 3 Co-occurrence of six key neuropathologies by clinical dementia status from data pooled across five cohorts (ACT, CC75C, CFAS FHS, and ROSMAP) Each bar represents the number of individuals with a unique combination of pathologies, as indicated by the filled in circles below. Individuals without dementia at death, who had a gap of greater than 2 years between the last study visit and death, were assigned a dementia status of missing in all studies except CFAS and CC75C, which included procedures to contact family informants in such circumstances. ACT=Adult Changes in Thought. CC75C=Cambridge City over-75s Cohort Study. CFAS=Cognitive Function and Ageing Studies. FHS=Framingham Heart Study. LATE-NC=limbic-predominant age-related TDP-43 encephalopathy neuropathologic change. ROSMAP=Religious Orders Study and Memory and Aging Project.
Figure 3 Co-occurrence of six key neuropathologies by clinical dementia status from data pooled across five cohorts (ACT, CC75C, CFAS FHS, and ROSMAP) Each bar represents the number of individuals with a unique combination of pathologies, as indicated by the filled in circles below. Individuals without dementia at death, who had a gap of greater than 2 years between the last study visit and death, were assigned a dementia status of missing in all studies except CFAS and CC75C, which included procedures to contact family informants in such circumstances. ACT=Adult Changes in Thought. CC75C=Cambridge City over-75s Cohort Study. CFAS=Cognitive Function and Ageing Studies. FHS=Framingham Heart Study. LATE-NC=limbic-predominant age-related TDP-43 encephalopathy neuropathologic change. ROSMAP=Religious Orders Study and Memory and Aging Project.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

Sorted by citations

Items 101–108 of 108

Metadata

Authors
Nichols, E., Merrick, R., Hay, S. I., Himali, D., Himali, J. J., Hunter, S., Keage, H. A. D., Latimer, C. S., Scott, M. R., Steinmetz, J. D., Walker, J. M., Wharton, S. B., Wiedner, C. D., Crane, P. K., Keene, C. D., Launer, L. J., Matthews, F. E., Schneider, J., Seshadri, S., White, L., Brayne, C., & Vos, T.
Affiliations
  • University of Washington (US)
  • University of Cambridge (GB)
  • Framingham Heart Study (US)
  • Boston University (US)
  • University of South Australia (AU)
  • Icahn School of Medicine at Mount Sinai (US)
  • University of Sheffield (GB)
  • The University of Texas at San Antonio Health Science Center (US)
  • National Institute on Aging (US)
  • Newcastle University (GB)
  • Rush University Medical Center (US)
  • Pacific Health Research and Education Institute (US)
Corresponding author
Nichols, Emma
Venue
The Lancet Healthy Longevity
Publisher
Elsevier BV
Published
2023-03
Volume
4
Issue
3
Pages
e115-e125
ISSN
2666-7568 (ISSN-L)
OpenAlex
W4322722320
Cited by
108
References
43
Citations by year
2026: 35 · 2025: 37 · 2024: 26 · 2023: 10
FWCI
21.99
Type
journal article
Language
en
Open access
Locations
  • The Lancet Healthy Longevity (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Repository@Hull (Worktribe) (University of Hull) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • UniSA Research Outputs Repository (University of South Australia) (submittedVersion, other-oa)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by-nc)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
  • National Institutes of Health (AG054076, AG049607, HHSN268201500001I, AG059421, AG066524, AG033090, 75N92019D00031, N01-HC-25195)
  • National Institute for Health and Care Research
  • Office of Research and Development
  • Nancy and Buster Alvord Endowment
  • National Heart, Lung, and Blood Institute (5 R01 NS041265)
  • Bill and Melinda Gates Foundation
  • Alzheimer’s Research UK (N01-AG-4-2149, 5 R01 AG017155, N01-HC-05102, 1 UO1 AG19349, ARUK-PhD2017-34)
  • Alzheimer’s Disease Research Center, University of Washington (P30 AG066509)
  • National Institute on Aging (U19AG066567, U01AG006781)
  • U.S. Department of Veterans Affairs
  • National Institute of Neurological Disorders and Stroke (UF1NS125513, NS017950, AG062531)
  • Medical Research Council (G0400077, G9901400, G0900582, U.1052.00.0013)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Autopsy, Cross-Sectional Studies, Dementia, Female, Humans, Male, Prevalence, Cerebral Amyloid Angiopathy, Limbic Encephalitis, Atherosclerosis, TDP-43 Proteinopathies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review